TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2020 DA - 2020// TI - Cancer statistics, 2020 JO - CA Cancer J Clin VL - 70 UR - https://doi.org/10.3322/caac.21590 DO - 10.3322/caac.21590 ID - Siegel2020 ER - TY - STD TI - Canadian Government. Canadian Cancer Statistics 2019. https://cancer.ca/Canadian-Cancer-Statistics-2019-EN. UR - http://cancer.ca/Canadian-Cancer-Statistics-2019-EN ID - ref2 ER - TY - STD TI - European Commission. ECIS—European Cancer Information. ecis.jrc.ec.europa.eu ID - ref3 ER - TY - JOUR AU - Lheureux, S. AU - Braunstein, M. AU - Oza, A. M. PY - 2019 DA - 2019// TI - Epithelial ovarian cancer: evolution of management in the era of precision medicine JO - CA Cancer J Clin VL - 68 ID - Lheureux2019 ER - TY - JOUR AU - Shih, I. -. M. AU - Kurman, R. J. PY - 2004 DA - 2004// TI - Ovarian tumorigenesis JO - Am J Pathol VL - 164 UR - https://doi.org/10.1016/S0002-9440(10)63708-X DO - 10.1016/S0002-9440(10)63708-X ID - Shih2004 ER - TY - JOUR AU - Pearce, C. L. AU - Templeman, C. AU - Rossing, M. A. AU - Lee, A. AU - Near, A. M. AU - Webb, P. M. PY - 2012 DA - 2012// TI - Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(11)70404-1 DO - 10.1016/S1470-2045(11)70404-1 ID - Pearce2012 ER - TY - JOUR AU - Kurman, R. J. AU - Shih, I. -. M. PY - 2016 DA - 2016// TI - The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded JO - Am J Pathol VL - 186 UR - https://doi.org/10.1016/j.ajpath.2015.11.011 DO - 10.1016/j.ajpath.2015.11.011 ID - Kurman2016 ER - TY - JOUR AU - Kurman, R. J. PY - 2013 DA - 2013// TI - Origin and molecular pathogenesis of ovarian high-grade serous carcinoma JO - Ann Oncol VL - 24 UR - https://doi.org/10.1093/annonc/mdt463 DO - 10.1093/annonc/mdt463 ID - Kurman2013 ER - TY - JOUR AU - Jacobs, I. J. AU - Menon, U. AU - Ryan, A. AU - Gentry-Maharaj, A. AU - Burnell, M. AU - Kalsi, J. K. PY - 2016 DA - 2016// TI - Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial JO - The Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(15)01224-6 DO - 10.1016/S0140-6736(15)01224-6 ID - Jacobs2016 ER - TY - JOUR AU - Menon, U. AU - Karpinskyj, C. AU - Gentry-Maharaj, A. PY - 2018 DA - 2018// TI - Ovarian cancer prevention and screening JO - Obstet Gynecol VL - 131 UR - https://doi.org/10.1097/AOG.0000000000002580 DO - 10.1097/AOG.0000000000002580 ID - Menon2018 ER - TY - JOUR AU - Torre, L. A. AU - Trabert, B. AU - DeSantis, C. E. AU - Miller, K. D. AU - Samimi, G. AU - Runowicz, C. D. PY - 2018 DA - 2018// TI - Ovarian cancer statistics, 2018 JO - CA Cancer J Clin. VL - 68 UR - https://doi.org/10.3322/caac.21456 DO - 10.3322/caac.21456 ID - Torre2018 ER - TY - JOUR AU - Goff, B. A. AU - Mandel, L. S. AU - Melancon, C. H. AU - Muntz, H. G. PY - 2004 DA - 2004// TI - Frequency of symptoms of ovarian cancer in women presenting to primary care clinics JO - JAMA VL - 291 UR - https://doi.org/10.1001/jama.291.22.2705 DO - 10.1001/jama.291.22.2705 ID - Goff2004 ER - TY - JOUR AU - Lheureux, S. AU - Gourley, C. AU - Vergote, I. AU - Oza, A. M. PY - 2019 DA - 2019// TI - Epithelial ovarian cancer JO - The Lancet VL - 393 UR - https://doi.org/10.1016/S0140-6736(18)32552-2 DO - 10.1016/S0140-6736(18)32552-2 ID - Lheureux2019 ER - TY - JOUR AU - Kehoe, S. AU - Hook, J. AU - Nankivell, M. AU - Jayson, G. C. AU - Kitchener, H. AU - Lopes, T. PY - 2015 DA - 2015// TI - Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial JO - The Lancet VL - 386 UR - https://doi.org/10.1016/S0140-6736(14)62223-6 DO - 10.1016/S0140-6736(14)62223-6 ID - Kehoe2015 ER - TY - JOUR AU - Vergote, I. AU - Tropé, C. G. AU - Amant, F. AU - Kristensen, G. B. AU - Ehlen, T. AU - Johnson, N. PY - 2010 DA - 2010// TI - Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa0908806 DO - 10.1056/NEJMoa0908806 ID - Vergote2010 ER - TY - JOUR AU - Siegel, R. AU - Naishadham, D. AU - Jemal, A. PY - 2012 DA - 2012// TI - Cancer statistics, 2012 JO - CA Cancer J Clin. VL - 62 UR - https://doi.org/10.3322/caac.20138 DO - 10.3322/caac.20138 ID - Siegel2012 ER - TY - JOUR PY - 2011 DA - 2011// TI - Integrated genomic analyses of ovarian carcinoma JO - Nature VL - 474 UR - https://doi.org/10.1038/nature10166 DO - 10.1038/nature10166 ID - ref17 ER - TY - JOUR AU - Vang, R. AU - Levine, D. A. AU - Soslow, R. A. AU - Zaloudek, C. AU - Shih, I. -. M. AU - Kurman, R. J. PY - 2016 DA - 2016// TI - Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma JO - Int J Gynecol Pathol VL - 35 UR - https://doi.org/10.1097/PGP.0000000000000207 DO - 10.1097/PGP.0000000000000207 ID - Vang2016 ER - TY - JOUR AU - Ahmed, A. A. AU - Etemadmoghadam, D. AU - Temple, J. AU - Lynch, A. G. AU - Riad, M. AU - Sharma, R. PY - 2010 DA - 2010// TI - Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary JO - J Pathol VL - 221 UR - https://doi.org/10.1002/path.2696 DO - 10.1002/path.2696 ID - Ahmed2010 ER - TY - JOUR AU - Labidi-Galy, S. I. AU - Papp, E. AU - Hallberg, D. AU - Niknafs, N. AU - Adleff, V. AU - Noe, M. PY - 2017 DA - 2017// TI - High grade serous ovarian carcinomas originate in the fallopian tube JO - Nat Commun VL - 8 UR - https://doi.org/10.1038/s41467-017-00962-1 DO - 10.1038/s41467-017-00962-1 ID - Labidi-Galy2017 ER - TY - JOUR AU - Konstantinopoulos, P. A. AU - Ceccaldi, R. AU - Shapiro, G. I. AU - D'Andrea, A. D. PY - 2015 DA - 2015// TI - Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer JO - Cancer Discov VL - 5 UR - https://doi.org/10.1158/2159-8290.CD-15-0714 DO - 10.1158/2159-8290.CD-15-0714 ID - Konstantinopoulos2015 ER - TY - JOUR AU - Macintyre, G. AU - Goranova, T. E. AU - Silva, D. AU - Ennis, D. AU - Piskorz, A. M. AU - Eldridge, M. PY - 2018 DA - 2018// TI - Copy number signatures and mutational processes in ovarian carcinoma JO - Nat Genet VL - 50 UR - https://doi.org/10.1038/s41588-018-0179-8 DO - 10.1038/s41588-018-0179-8 ID - Macintyre2018 ER - TY - JOUR AU - Tothill, R. W. AU - Tinker, A. V. AU - George, J. AU - Brown, R. AU - Fox, S. B. AU - Lade, S. PY - 2008 DA - 2008// TI - Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-08-0196 DO - 10.1158/1078-0432.CCR-08-0196 ID - Tothill2008 ER - TY - JOUR AU - Konecny, G. E. AU - Wang, C. AU - Hamidi, H. AU - Winterhoff, B. AU - Kalli, K. R. AU - Dering, J. PY - 2014 DA - 2014// TI - Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer JO - JNCIJ VL - 106 ID - Konecny2014 ER - TY - JOUR AU - Verhaak, R. G. W. AU - Tamayo, P. AU - Yang, J. -. Y. AU - Hubbard, D. AU - Zhang, H. AU - Creighton, C. J. PY - 2012 DA - 2012// TI - Prognostically relevant gene signatures of high-grade serous ovarian carcinoma JO - J Clin Investig VL - 365 ID - Verhaak2012 ER - TY - JOUR AU - Leong, H. S. AU - Galletta, L. AU - Etemadmoghadam, D. AU - George, J. AU - Köbel, M. PY - 2015 DA - 2015// TI - Efficient molecular subtype classification of high-grade serous ovarian cancer JO - J Pathol VL - 236 UR - https://doi.org/10.1002/path.4536 DO - 10.1002/path.4536 ID - Leong2015 ER - TY - JOUR AU - Zhang, H. AU - Liu, T. AU - Zhang, Z. AU - Payne, S. H. AU - Zhang, B. AU - McDermott, J. E. PY - 2016 DA - 2016// TI - Integrated proteogenomic characterization of human high-grade serous ovarian cancer JO - Cell VL - 166 UR - https://doi.org/10.1016/j.cell.2016.05.069 DO - 10.1016/j.cell.2016.05.069 ID - Zhang2016 ER - TY - JOUR AU - Hoogstraat, M. AU - Pagter, M. S. AU - Cirkel, G. A. AU - Roosmalen, M. J. AU - Harkins, T. T. AU - Duran, K. PY - 2014 DA - 2014// TI - Genomic and transcriptomic plasticity in treatment-naive ovarian cancer JO - Genome Res VL - 24 UR - https://doi.org/10.1101/gr.161026.113 DO - 10.1101/gr.161026.113 ID - Hoogstraat2014 ER - TY - JOUR AU - Schwarz, R. F. AU - Ng, C. K. Y. AU - Cooke, S. L. AU - Newman, S. AU - Temple, J. AU - Piskorz, A. M. PY - 2015 DA - 2015// TI - Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis JO - PLOS Med VL - 12 UR - https://doi.org/10.1371/journal.pmed.1001789 DO - 10.1371/journal.pmed.1001789 ID - Schwarz2015 ER - TY - JOUR AU - Bashashati, A. AU - Ha, G. AU - Tone, A. AU - Ding, J. AU - Prentice, L. M. AU - Roth, A. PY - 2013 DA - 2013// TI - Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling JO - J Pathol VL - 231 UR - https://doi.org/10.1002/path.4230 DO - 10.1002/path.4230 ID - Bashashati2013 ER - TY - JOUR AU - Hunt, A. L. AU - Bateman, N. W. AU - Hood, B. L. AU - Conrads, K. A. AU - Zhou, M. AU - Litzi, T. J. PY - 2019 DA - 2019// TI - Extensive intratumor proteogenomic heterogeneity revealed by multiregion sampling in a high-grade serous ovarian tumor specimen JO - Cancer Res VL - 12 ID - Hunt2019 ER - TY - JOUR AU - McPherson, A. AU - Roth, A. AU - Laks, E. AU - Masud, T. AU - Bashashati, A. AU - Zhang, A. W. PY - 2016 DA - 2016// TI - Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer JO - Nat Genet VL - 48 UR - https://doi.org/10.1038/ng.3573 DO - 10.1038/ng.3573 ID - McPherson2016 ER - TY - JOUR AU - Masoodi, T. AU - Siraj, S. AU - Siraj, A. K. AU - Azam, S. AU - Qadri, Z. AU - Parvathareddy, S. K. PY - 2020 DA - 2020// TI - Genetic heterogeneity and evolutionary history of high-grade ovarian carcinoma and matched distant metastases JO - Br J Cancer VL - 122 UR - https://doi.org/10.1038/s41416-020-0763-4 DO - 10.1038/s41416-020-0763-4 ID - Masoodi2020 ER - TY - JOUR AU - Eckert, M. A. AU - Coscia, F. AU - Chryplewicz, A. AU - Chang, J. W. AU - Hernandez, K. M. AU - Pan, S. PY - 2019 DA - 2019// TI - Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts JO - Nature VL - 569 UR - https://doi.org/10.1038/s41586-019-1173-8 DO - 10.1038/s41586-019-1173-8 ID - Eckert2019 ER - TY - JOUR AU - Izar, B. AU - Tirosh, I. AU - Stover, E. H. AU - Wakiro, I. AU - Cuoco, M. S. AU - Alter, I. PY - 2020 DA - 2020// TI - A single-cell landscape of high-grade serous ovarian cancer JO - Nat Med VL - 26 UR - https://doi.org/10.1038/s41591-020-0926-0 DO - 10.1038/s41591-020-0926-0 ID - Izar2020 ER - TY - JOUR AU - Hu, Z. AU - Artibani, M. AU - Alsaadi, A. AU - Wietek, N. AU - Morotti, M. AU - Shi, T. PY - 2020 DA - 2020// TI - The repertoire of serous ovarian cancer non- genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells JO - Cancer Cell VL - 37 UR - https://doi.org/10.1016/j.ccell.2020.01.003 DO - 10.1016/j.ccell.2020.01.003 ID - Hu2020 ER - TY - JOUR AU - Bast, R. C. AU - Skates, S. AU - Lokshin, A. AU - Moore, R. G. PY - 2012 DA - 2012// TI - Differential diagnosis of a pelvic mass JO - Int J Gynecol Cancer VL - 22 UR - https://doi.org/10.1097/IGC.0b013e318251c97d DO - 10.1097/IGC.0b013e318251c97d ID - Bast2012 ER - TY - JOUR AU - Giede, K. C. AU - Kieser, K. AU - Dodge, J. AU - Rosen, B. PY - 2005 DA - 2005// TI - Who should operate on patients with ovarian cancer? An evidence-based review JO - Gynecol Oncol VL - 99 UR - https://doi.org/10.1016/j.ygyno.2005.07.008 DO - 10.1016/j.ygyno.2005.07.008 ID - Giede2005 ER - TY - JOUR AU - Rustin, G. J. S. AU - Bast, R. C. AU - Kelloff, G. J. AU - Barrett, J. C. AU - Carter, S. K. AU - Nisen, P. D. PY - 2004 DA - 2004// TI - Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer JO - Clin Cancer Res VL - 10 UR - https://doi.org/10.1158/1078-0432.CCR-03-0787 DO - 10.1158/1078-0432.CCR-03-0787 ID - Rustin2004 ER - TY - JOUR AU - Fleming, N. D. AU - Cass, I. AU - Walsh, C. S. AU - Karlan, B. Y. AU - Li, A. J. PY - 2011 DA - 2011// TI - CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer JO - Gynecol Oncol VL - 121 UR - https://doi.org/10.1016/j.ygyno.2011.01.014 DO - 10.1016/j.ygyno.2011.01.014 ID - Fleming2011 ER - TY - JOUR AU - Bast, R. C. AU - Klug, T. L. AU - John, E. S. AU - Jenison, E. AU - Niloff, J. M. AU - Lazarus, H. PY - 1983 DA - 1983// TI - A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer JO - N Engl J Med VL - 309 UR - https://doi.org/10.1056/NEJM198310133091503 DO - 10.1056/NEJM198310133091503 ID - Bast1983 ER - TY - JOUR AU - Høgdall, E. V. S. AU - Christensen, L. AU - Kjaer, S. K. AU - Blaakaer, J. AU - Kjærbye-Thygesen, A. AU - Gayther, S. PY - 2007 DA - 2007// TI - CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients JO - Gynecol Oncol VL - 104 UR - https://doi.org/10.1016/j.ygyno.2006.09.028 DO - 10.1016/j.ygyno.2006.09.028 ID - Høgdall2007 ER - TY - JOUR AU - Jacobs, I. AU - Bast, R. C. PY - 1989 DA - 1989// TI - The CA 125 tumour-associated antigen: a review of the literature JO - Hum Reprod VL - 4 UR - https://doi.org/10.1093/oxfordjournals.humrep.a136832 DO - 10.1093/oxfordjournals.humrep.a136832 ID - Jacobs1989 ER - TY - JOUR AU - Buamah, P. PY - 2000 DA - 2000// TI - Benign conditions associated with raised serum CA-125 concentration JO - J Surg Oncol VL - 75 UR - https://doi.org/3.0.CO;2-Q DO - 3.0.CO;2-Q ID - Buamah2000 ER - TY - JOUR AU - Nossov, V. AU - Amneus, M. AU - Su, F. AU - Lang, J. AU - Janco, J. M. T. AU - Reddy, S. T. PY - 2008 DA - 2008// TI - The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? JO - Am J Obstet Gynecol VL - 199 UR - https://doi.org/10.1016/j.ajog.2008.04.009 DO - 10.1016/j.ajog.2008.04.009 ID - Nossov2008 ER - TY - JOUR AU - Jacobs, I. AU - Oram, D. AU - Fairbanks, J. AU - Turner, J. AU - Frost, C. AU - Grudzinskas, J. G. PY - 1990 DA - 1990// TI - A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer JO - Br J Obstet Gynaecol VL - 97 UR - https://doi.org/10.1111/j.1471-0528.1990.tb02448.x DO - 10.1111/j.1471-0528.1990.tb02448.x ID - Jacobs1990 ER - TY - JOUR AU - Calster, B. AU - Hoorde, K. AU - Valentin, L. AU - Testa, A. C. AU - Fischerova, D. AU - Holsbeke, C. PY - 2014 DA - 2014// TI - Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study JO - BMJ VL - 349 UR - https://doi.org/10.1136/bmj.g5920 DO - 10.1136/bmj.g5920 ID - Calster2014 ER - TY - JOUR AU - Pinsky, P. F. AU - Yu, K. AU - Kramer, B. S. AU - Black, A. AU - Buys, S. S. AU - Partridge, E. PY - 2016 DA - 2016// TI - Extended mortality results for ovarian cancer screening in the PLCO trial with median 15 years follow-up JO - Gynecol Oncol VL - 143 UR - https://doi.org/10.1016/j.ygyno.2016.08.334 DO - 10.1016/j.ygyno.2016.08.334 ID - Pinsky2016 ER - TY - JOUR AU - Rustin, G. J. S. AU - Nelstrop, A. E. AU - Tuxen, M. K. AU - Lambert, H. E. PY - 1996 DA - 1996// TI - Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group study JO - Ann Oncol VL - 7 UR - https://doi.org/10.1093/oxfordjournals.annonc.a010602 DO - 10.1093/oxfordjournals.annonc.a010602 ID - Rustin1996 ER - TY - JOUR AU - Rustin, G. J. AU - Marples, M. AU - Nelstrop, A. E. AU - Mahmoudi, M. AU - Meyer, T. PY - 2001 DA - 2001// TI - Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels JO - J Clin Oncol VL - 19 UR - https://doi.org/10.1200/JCO.2001.19.20.4054 DO - 10.1200/JCO.2001.19.20.4054 ID - Rustin2001 ER - TY - JOUR AU - Santillan, A. AU - Garg, R. AU - Zahurak, M. L. AU - Gardner, G. J. AU - Giuntoli, R. L. AU - Armstrong, D. K. PY - 2005 DA - 2005// TI - Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.02.2582 DO - 10.1200/JCO.2005.02.2582 ID - Santillan2005 ER - TY - JOUR AU - Wilder, J. L. AU - Pavlik, E. AU - Straughn, J. M. AU - Kirby, T. AU - Higgins, R. V. AU - DePriest, P. D. PY - 2003 DA - 2003// TI - Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation☆ JO - Gynecol Oncol VL - 89 UR - https://doi.org/10.1016/S0090-8258(03)00051-9 DO - 10.1016/S0090-8258(03)00051-9 ID - Wilder2003 ER - TY - JOUR AU - Rustin, G. J. AU - Burg, M. E. AU - Griffin, C. L. AU - Guthrie, D. AU - Lamont, A. AU - Jayson, G. C. PY - 2010 DA - 2010// TI - Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial JO - The Lancet VL - 376 UR - https://doi.org/10.1016/S0140-6736(10)61268-8 DO - 10.1016/S0140-6736(10)61268-8 ID - Rustin2010 ER - TY - JOUR AU - Niloff, J. M. AU - Bast, R. C. AU - Schaetzl, E. M. AU - Knapp, R. C. PY - 1985 DA - 1985// TI - Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer JO - Am J Obstet Gynecol VL - 151 UR - https://doi.org/10.1016/0002-9378(85)90678-7 DO - 10.1016/0002-9378(85)90678-7 ID - Niloff1985 ER - TY - JOUR AU - Aravantinos, D. AU - Michalas, S. AU - Papazefkos, V. AU - Christoforaki, M. AU - Stypsaneli, A. AU - Vlachos, G. PY - 1990 DA - 1990// TI - Predictive values of CA 125 antigen levels and CT scan in second-look procedures for ovarian cancer JO - Eur J Obstet Gynecol Reprod Biol VL - 37 UR - https://doi.org/10.1016/0028-2243(90)90034-X DO - 10.1016/0028-2243(90)90034-X ID - Aravantinos1990 ER - TY - JOUR AU - Drapkin, R. AU - Horsten, H. H. AU - Lin, Y. AU - Mok, S. C. AU - Crum, C. P. AU - Welch, W. R. PY - 2005 DA - 2005// TI - Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas JO - Cancer Res VL - 65 UR - https://doi.org/10.1158/0008-5472.CAN-04-3924 DO - 10.1158/0008-5472.CAN-04-3924 ID - Drapkin2005 ER - TY - JOUR AU - Hellström, I. AU - Raycraft, J. AU - Hayden-Ledbetter, M. AU - Ledbetter, J. A. AU - Schummer, M. AU - McIntosh, M. PY - 2003 DA - 2003// TI - The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma JO - Can Res VL - 63 ID - Hellström2003 ER - TY - JOUR AU - Moore, R. G. AU - Brown, A. K. AU - Miller, M. C. AU - Skates, S. AU - Allard, W. J. AU - Verch, T. PY - 2008 DA - 2008// TI - The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass JO - Gynecol Oncol VL - 108 UR - https://doi.org/10.1016/j.ygyno.2007.10.017 DO - 10.1016/j.ygyno.2007.10.017 ID - Moore2008 ER - TY - JOUR AU - Abdel-Azeez, H. A. AU - Labib, H. A. AU - Sharaf, S. M. AU - Refai, A. N. PY - 2010 DA - 2010// TI - HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses JO - Asian Pac J Cancer Prev VL - 11 ID - Abdel-Azeez2010 ER - TY - JOUR AU - Holcomb, K. AU - Vucetic, Z. AU - Miller, M. C. AU - Knapp, R. C. PY - 2010 DA - 2010// TI - Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women JO - YMOB VL - 205 ID - Holcomb2010 ER - TY - JOUR AU - Yanaranop, M. AU - Anakrat, V. AU - Siricharoenthai, S. AU - Nakrangsee, S. AU - Thinkhamrop, B. PY - 2017 DA - 2017// TI - Is the risk of ovarian malignancy algorithm better than other tests for predicting ovarian malignancy in women with pelvic masses? JO - Gynecol Obstet Investig VL - 82 UR - https://doi.org/10.1159/000446238 DO - 10.1159/000446238 ID - Yanaranop2017 ER - TY - JOUR AU - Huhtinen, K. AU - Suvitie, P. AU - Hiissa, J. AU - Junnila, J. AU - Huvila, J. AU - Kujari, H. PY - 2009 DA - 2009// TI - Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts JO - Br J Cancer VL - 100 UR - https://doi.org/10.1038/sj.bjc.6605011 DO - 10.1038/sj.bjc.6605011 ID - Huhtinen2009 ER - TY - JOUR AU - Rosen, D. G. AU - Wang, L. AU - Atkinson, J. N. AU - Yu, Y. AU - Lu, K. H. AU - Diamandis, E. P. PY - 2005 DA - 2005// TI - Potential markers that complement expression of CA125 in epithelial ovarian cancer JO - Gynecol Oncol VL - 99 UR - https://doi.org/10.1016/j.ygyno.2005.06.040 DO - 10.1016/j.ygyno.2005.06.040 ID - Rosen2005 ER - TY - JOUR AU - Plotti, F. AU - Capriglione, S. AU - Terranova, C. AU - Montera, R. AU - Aloisi, A. AU - Damiani, P. PY - 2012 DA - 2012// TI - Does HE4 have a role as biomarker in the recurrence of ovarian cancer? JO - Tumor Biol VL - 33 UR - https://doi.org/10.1007/s13277-012-0471-7 DO - 10.1007/s13277-012-0471-7 ID - Plotti2012 ER - TY - JOUR AU - Anastasi, E. AU - Giovanna Marchei, G. AU - Viggiani, V. AU - Gennarini, G. AU - Frati, L. AU - Reale, M. G. PY - 2010 DA - 2010// TI - HE4: a new potential early biomarker for the recurrence of ovarian cancer JO - Tumor Biol VL - 31 UR - https://doi.org/10.1007/s13277-009-0015-y DO - 10.1007/s13277-009-0015-y ID - Anastasi2010 ER - TY - JOUR AU - Schummer, M. AU - Drescher, C. AU - Forrest, R. AU - Gough, S. AU - Thorpe, J. AU - Hellström, I. PY - 2012 DA - 2012// TI - Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125 JO - Gynecol Oncol VL - 125 UR - https://doi.org/10.1016/j.ygyno.2011.11.050 DO - 10.1016/j.ygyno.2011.11.050 ID - Schummer2012 ER - TY - JOUR AU - Plotti, F. AU - Guzzo, F. AU - Schirò, T. AU - Terranova, C. AU - Cicco, N. C. AU - Montera, R. PY - 2019 DA - 2019// TI - Role of human epididymis protein 4 (HE4) in detecting recurrence in CA125 negative ovarian cancer patients JO - Int J Gynecol Cancer VL - 29 UR - https://doi.org/10.1136/ijgc-2019-000211 DO - 10.1136/ijgc-2019-000211 ID - Plotti2019 ER - TY - JOUR AU - Nassir, M. AU - Guan, J. AU - Luketina, H. AU - Siepmann, T. AU - Rohr, I. AU - Richter, R. PY - 2015 DA - 2015// TI - The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients—results from the OVCAD study JO - Tumor Biol VL - 37 UR - https://doi.org/10.1007/s13277-015-4031-9 DO - 10.1007/s13277-015-4031-9 ID - Nassir2015 ER - TY - JOUR AU - Moore, R. G. AU - Miller, M. C. AU - DiSilvestro, P. AU - Landrum, L. M. AU - Gajewski, W. AU - Ball, J. J. PY - 2011 DA - 2011// TI - Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass JO - Obstet Gynecol VL - 118 UR - https://doi.org/10.1097/AOG.0b013e318224fce2 DO - 10.1097/AOG.0b013e318224fce2 ID - Moore2011 ER - TY - JOUR AU - Moore, R. G. AU - McMeekin, D. S. AU - Brown, A. K. AU - DiSilvestro, P. AU - Miller, M. C. AU - Allard, W. J. PY - 2009 DA - 2009// TI - A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass JO - Gynecol Oncol VL - 112 UR - https://doi.org/10.1016/j.ygyno.2008.08.031 DO - 10.1016/j.ygyno.2008.08.031 ID - Moore2009 ER - TY - JOUR AU - Li, F. AU - Tie, R. AU - Chang, K. AU - Wang, F. AU - Deng, S. AU - Lu, W. PY - 2012 DA - 2012// TI - Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and ca125 in predicting epithelial ovarian cancer: a meta-analysis JO - BMC Cancer VL - 12 UR - https://doi.org/10.1186/1471-2407-12-1 DO - 10.1186/1471-2407-12-1 ID - Li2012 ER - TY - JOUR AU - Moore, R. G. AU - Jabre-Raughley, M. AU - Brown, A. K. AU - Robison, K. M. AU - Miller, M. C. AU - Allard, W. J. PY - 2010 DA - 2010// TI - Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass JO - Am J Obstet Gynecol VL - 203 UR - https://doi.org/10.1016/j.ajog.2010.03.043 DO - 10.1016/j.ajog.2010.03.043 ID - Moore2010 ER - TY - JOUR AU - Lennox, G. K. AU - Eiriksson, L. R. AU - Reade, C. J. AU - Leung, F. AU - Mojtahedi, G. AU - Atenafu, E. G. PY - 2015 DA - 2015// TI - Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter? JO - Int J Gynecol Cancer VL - 25 UR - https://doi.org/10.1097/IGC.0000000000000442 DO - 10.1097/IGC.0000000000000442 ID - Lennox2015 ER - TY - JOUR AU - Zhang, Z. AU - Chan, D. W. PY - 2010 DA - 2010// TI - The road from discovery to clinical diagnostics: lessons learned from the first FDA-Cleared in vitro diagnostic multivariate index assay of proteomic biomarkers JO - Cancer Epidemiol Biomark Prev VL - 19 UR - https://doi.org/10.1158/1055-9965.EPI-10-0580 DO - 10.1158/1055-9965.EPI-10-0580 ID - Zhang2010 ER - TY - JOUR AU - Ueland, F. R. AU - Desimone, C. P. AU - Seamon, L. G. AU - Miller, R. A. AU - Goodrich, S. AU - Podzielinski, I. PY - 2011 DA - 2011// TI - Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors JO - Obstet Gynecol VL - 117 UR - https://doi.org/10.1097/AOG.0b013e31821b5118 DO - 10.1097/AOG.0b013e31821b5118 ID - Ueland2011 ER - TY - JOUR AU - Miller, R. W. AU - Smith, A. AU - Desimone, C. P. AU - Seamon, L. AU - Goodrich, S. AU - Podzielinski, I. PY - 2011 DA - 2011// TI - Performance of the American College of Obstetricians and Gynecologistsʼ ovarian tumor referral guidelines with a multivariate index assay JO - Obstet Gynecol VL - 117 UR - https://doi.org/10.1097/AOG.0b013e31821b1d80 DO - 10.1097/AOG.0b013e31821b1d80 ID - Miller2011 ER - TY - JOUR AU - Bristow, R. E. AU - Smith, A. AU - Zhang, Z. AU - Chan, D. W. AU - Crutcher, G. AU - Fung, E. T. PY - 2013 DA - 2013// TI - Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay JO - Gynecol Oncol VL - 128 UR - https://doi.org/10.1016/j.ygyno.2012.11.022 DO - 10.1016/j.ygyno.2012.11.022 ID - Bristow2013 ER - TY - JOUR AU - Coleman, R. L. AU - Herzog, T. J. AU - Chan, D. W. AU - Munroe, D. G. AU - Pappas, T. C. AU - Smith, A. PY - 2016 DA - 2016// TI - Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses JO - YMOB VL - 215 ID - Coleman2016 ER - TY - JOUR AU - Walsh, T. AU - Casadei, S. AU - Lee, M. K. AU - Pennil, C. C. AU - Nord, A. S. AU - Thornton, A. M. PY - 2011 DA - 2011// TI - Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing JO - Proc Natl Acad Sci USA VL - 108 UR - https://doi.org/10.1073/pnas.1115052108 DO - 10.1073/pnas.1115052108 ID - Walsh2011 ER - TY - JOUR AU - Chen, S. AU - Parmigiani, G. PY - 2007 DA - 2007// TI - Meta-analysis of BRCA1 and BRCA2 penetrance JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.09.1066 DO - 10.1200/JCO.2006.09.1066 ID - Chen2007 ER - TY - JOUR AU - Mavaddat, N. AU - Peock, S. AU - Frost, D. AU - Ellis, S. AU - Platte, R. AU - Fineberg, E. PY - 2013 DA - 2013// TI - Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE JO - JNCIJ VL - 105 UR - https://doi.org/10.1093/jnci/djt095 DO - 10.1093/jnci/djt095 ID - Mavaddat2013 ER - TY - JOUR AU - Kuchenbaecker, K. B. AU - Hopper, J. L. AU - Barnes, D. R. AU - Phillips, K. -. A. AU - Mooij, T. M. AU - Roos-Blom, M. -. J. PY - 2017 DA - 2017// TI - Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers JO - JAMA VL - 317 UR - https://doi.org/10.1001/jama.2017.7112 DO - 10.1001/jama.2017.7112 ID - Kuchenbaecker2017 ER - TY - JOUR AU - Lancaster, J. M. AU - Powell, C. B. AU - Chen, L. -. M. AU - Richardson, D. L. PY - 2015 DA - 2015// TI - Society of gynecologic oncology statement on risk assessment for inherited gynecologic cancer predispositions JO - Gynecol Oncol VL - 136 UR - https://doi.org/10.1016/j.ygyno.2014.09.009 DO - 10.1016/j.ygyno.2014.09.009 ID - Lancaster2015 ER - TY - JOUR AU - Scheuer, L. AU - Kauff, N. AU - Robson, M. AU - Kelly, B. AU - Barakat, R. AU - Satagopan, J. PY - 2002 DA - 2002// TI - Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.2002.20.5.1260 DO - 10.1200/JCO.2002.20.5.1260 ID - Scheuer2002 ER - TY - JOUR AU - Kauff, N. D. AU - Satagopan, J. M. AU - Robson, M. E. AU - Scheuer, L. AU - Hensley, M. AU - Hudis, C. A. PY - 2002 DA - 2002// TI - Risk-reducing salpingo-oophorectomy in women with a BRCA1or BRCA2 mutation JO - N Engl J Med VL - 346 UR - https://doi.org/10.1056/NEJMoa020119 DO - 10.1056/NEJMoa020119 ID - Kauff2002 ER - TY - JOUR AU - Alsop, K. AU - Fereday, S. AU - Meldrum, C. AU - deFazio, A. AU - Emmanuel, C. AU - George, J. PY - 2012 DA - 2012// TI - BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.39.8545 DO - 10.1200/JCO.2011.39.8545 ID - Alsop2012 ER - TY - JOUR AU - Lesnock, J. L. AU - Darcy, K. M. AU - Tian, C. AU - Deloia, J. A. AU - Thrall, M. M. AU - Zahn, C. PY - 2013 DA - 2013// TI - BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study JO - Br J Cancer VL - 108 UR - https://doi.org/10.1038/bjc.2013.70 DO - 10.1038/bjc.2013.70 ID - Lesnock2013 ER - TY - JOUR AU - Coleman, R. L. AU - Oza, A. M. AU - Lorusso, D. AU - Aghajanian, C. AU - Oaknin, A. AU - Dean, A. PY - 2017 DA - 2017// TI - Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial JO - The Lancet VL - 390 UR - https://doi.org/10.1016/S0140-6736(17)32440-6 DO - 10.1016/S0140-6736(17)32440-6 ID - Coleman2017 ER - TY - JOUR AU - Moore, K. AU - Colombo, N. AU - Scambia, G. AU - Kim, B. -. G. AU - Oaknin, A. AU - Friedlander, M. PY - 2018 DA - 2018// TI - Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1810858 DO - 10.1056/NEJMoa1810858 ID - Moore2018 ER - TY - JOUR AU - Matulonis, U. A. AU - Penson, R. T. AU - Domchek, S. M. AU - Kaufman, B. AU - Shapira-Frommer, R. AU - Audeh, M. W. PY - 2016 DA - 2016// TI - Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw133 DO - 10.1093/annonc/mdw133 ID - Matulonis2016 ER - TY - JOUR AU - Oza, A. M. AU - Tinker, A. V. AU - Oaknin, A. AU - Shapira-Frommer, R. AU - McNeish, I. A. AU - Swisher, E. M. PY - 2017 DA - 2017// TI - Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2 JO - Gynecol Oncol VL - 147 UR - https://doi.org/10.1016/j.ygyno.2017.08.022 DO - 10.1016/j.ygyno.2017.08.022 ID - Oza2017 ER - TY - JOUR AU - Pepe, M. S. AU - Etzioni, R. AU - Feng, Z. AU - Potter, J. D. AU - Thompson, M. L. AU - Thornquist, M. PY - 2001 DA - 2001// TI - Phases of biomarker development for early detection of cancer JO - JNCIJ VL - 93 UR - https://doi.org/10.1093/jnci/93.14.1054 DO - 10.1093/jnci/93.14.1054 ID - Pepe2001 ER - TY - JOUR AU - Wan, J. C. M. AU - Massie, C. AU - Garcia-Corbacho, J. AU - Mouliere, F. AU - Brenton, J. D. AU - Caldas, C. PY - 2017 DA - 2017// TI - Liquid biopsies come of age: towards implementation of circulating tumour DNA JO - Nat Rev Cancer VL - 17 UR - https://doi.org/10.1038/nrc.2017.7 DO - 10.1038/nrc.2017.7 ID - Wan2017 ER - TY - JOUR AU - Kamat, A. A. AU - Sood, A. K. AU - Dang, D. AU - Gershenson, D. M. AU - Simpson, J. L. AU - Bischoff, F. Z. PY - 2006 DA - 2006// TI - Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR JO - Ann N Y Acad Sci VL - 1075 UR - https://doi.org/10.1196/annals.1368.031 DO - 10.1196/annals.1368.031 ID - Kamat2006 ER - TY - JOUR AU - Zachariah, R. R. AU - Schmid, S. AU - Buerki, N. AU - Radpour, R. AU - Holzgreve, W. AU - Zhong, X. PY - 2008 DA - 2008// TI - Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors JO - Obstet Gynecol VL - 112 UR - https://doi.org/10.1097/AOG.0b013e3181867bc0 DO - 10.1097/AOG.0b013e3181867bc0 ID - Zachariah2008 ER - TY - JOUR AU - Shao, X. AU - He, Y. AU - Ji, M. AU - Chen, X. AU - Qi, J. AU - Shi, W. PY - 2015 DA - 2015// TI - Quantitative analysis of cell-free DNA in ovarian cancer JO - Oncol Lett VL - 10 UR - https://doi.org/10.3892/ol.2015.3771 DO - 10.3892/ol.2015.3771 ID - Shao2015 ER - TY - JOUR AU - Cohen, J. D. AU - Li, L. AU - Wang, Y. AU - Thoburn, C. AU - Afsari, B. AU - Danilova, L. PY - 2018 DA - 2018// TI - Detection and localization of surgically resectable cancers with a multi-analyte blood test JO - Science VL - 359 UR - https://doi.org/10.1126/science.aar3247 DO - 10.1126/science.aar3247 ID - Cohen2018 ER - TY - JOUR AU - Parkinson, C. A. AU - Gale, D. AU - Piskorz, A. M. AU - Biggs, H. AU - Hodgkin, C. AU - Addley, H. PY - 2016 DA - 2016// TI - Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study. Mardis ER, editor JO - PLOS Med VL - 13 UR - https://doi.org/10.1371/journal.pmed.1002198 DO - 10.1371/journal.pmed.1002198 ID - Parkinson2016 ER - TY - JOUR AU - Piskorz, A. AU - Lin, K. K. AU - Morris, J. A. AU - Mann, E. AU - Oza, A. M. AU - Coleman, R. L. PY - 2016 DA - 2016// TI - Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.34.15_suppl.5549 DO - 10.1200/JCO.2016.34.15_suppl.5549 ID - Piskorz2016 ER - TY - JOUR AU - Kim, Y. M. AU - Lee, S. W. AU - Lee, Y. J. AU - Lee, H. Y. AU - Lee, J. E. AU - Choi, E. K. PY - 2019 DA - 2019// TI - Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma JO - J Gynecol Oncol VL - 30 UR - https://doi.org/10.3802/jgo.2019.30.e32 DO - 10.3802/jgo.2019.30.e32 ID - Kim2019 ER - TY - JOUR AU - Vitale, S. R. AU - Groenendijk, F. H. AU - Marion, R. AU - Beaufort, C. M. AU - Helmijr, J. C. AU - Jan Dubbink, H. PY - 2020 DA - 2020// TI - TP53 mutations in serum circulating cell-free tumor DNA as longitudinal biomarker for high-grade serous ovarian cancer JO - Biomolecules VL - 10 UR - https://doi.org/10.3390/biom10030415 DO - 10.3390/biom10030415 ID - Vitale2020 ER - TY - JOUR AU - Christie, E. L. AU - Fereday, S. AU - Doig, K. AU - Pattnaik, S. AU - Dawson, S. -. J. AU - Bowtell, D. D. L. PY - 2017 DA - 2017// TI - Reversion of BRCA1/2Germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.70.4627 DO - 10.1200/JCO.2016.70.4627 ID - Christie2017 ER - TY - JOUR AU - Bettegowda, C. AU - Sausen, M. AU - Leary, R. J. AU - Kinde, I. AU - Wang, Y. AU - Agrawal, N. PY - 2014 DA - 2014// TI - Detection of circulating tumor DNA in early- and late-stage human malignancies JO - Sci Transl Med VL - 6 UR - https://doi.org/10.1126/scitranslmed.3007094 DO - 10.1126/scitranslmed.3007094 ID - Bettegowda2014 ER - TY - JOUR AU - Harris, F. R. AU - Kovtun, I. V. AU - Smadbeck, J. AU - Multinu, F. AU - Jatoi, A. AU - Kosari, F. PY - 2016 DA - 2016// TI - Quantification of somatic chromosomal rearrangements in circulating cell-free DNA from ovarian cancers JO - Sci Rep VL - 6 UR - https://doi.org/10.1038/s41598-016-0001-8 DO - 10.1038/s41598-016-0001-8 ID - Harris2016 ER - TY - JOUR AU - Shen, S. Y. AU - Singhania, R. AU - Fehringer, G. AU - Chakravarthy, A. AU - Roehrl, M. H. A. AU - Chadwick, D. PY - 2018 DA - 2018// TI - Sensitive tumour detection and classification using plasma cell-free DNA methylomes JO - Nature VL - 563 UR - https://doi.org/10.1038/s41586-018-0703-0 DO - 10.1038/s41586-018-0703-0 ID - Shen2018 ER - TY - JOUR AU - Widschwendter, M. AU - Zikan, M. AU - Wahl, B. AU - Lempiäinen, H. AU - Paprotka, T. AU - Evans, I. PY - 2017 DA - 2017// TI - The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer JO - Genome Med VL - 9 UR - https://doi.org/10.1186/s13073-016-0392-y DO - 10.1186/s13073-016-0392-y ID - Widschwendter2017 ER - TY - JOUR AU - Peng, Y. AU - Croce, C. M. PY - 2016 DA - 2016// TI - The role of MicroRNAs in human cancer JO - Sig Transduct Target Ther VL - 1 UR - https://doi.org/10.1038/sigtrans.2015.4 DO - 10.1038/sigtrans.2015.4 ID - Peng2016 ER - TY - JOUR AU - Li, L. AU - Zhu, D. AU - Huang, L. AU - Zhang, J. AU - Bian, Z. AU - Chen, X. PY - 2012 DA - 2012// TI - Argonaute 2 complexes selectively protect the circulating MicroRNAs in cell-secreted microvesicles. Starczynowski DT, editor JO - PLoS ONE VL - 7 UR - https://doi.org/10.1371/journal.pone.0046957 DO - 10.1371/journal.pone.0046957 ID - Li2012 ER - TY - JOUR AU - Mitchell, P. S. AU - Parkin, R. K. AU - Kroh, E. M. AU - Fritz, B. R. AU - Wyman, S. K. AU - Pogosova-Agadjanyan, E. L. PY - 2008 DA - 2008// TI - Circulating microRNAs as stable blood-based markers for cancer detection JO - Proc Natl Acad Sci USA VL - 105 UR - https://doi.org/10.1073/pnas.0804549105 DO - 10.1073/pnas.0804549105 ID - Mitchell2008 ER - TY - JOUR AU - Todeschini, P. AU - Salviato, E. AU - Paracchini, L. AU - Ferracin, M. AU - Petrillo, M. AU - Zanotti, L. PY - 2017 DA - 2017// TI - Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: a validation across two independent cohorts JO - Cancer Lett VL - 388 UR - https://doi.org/10.1016/j.canlet.2016.12.017 DO - 10.1016/j.canlet.2016.12.017 ID - Todeschini2017 ER - TY - JOUR AU - Shah, J. S. AU - Gard, G. B. AU - Yang, J. AU - Maidens, J. AU - Valmadre, S. AU - Soon, P. S. PY - 2018 DA - 2018// TI - Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer JO - Gynecol Oncol VL - 148 UR - https://doi.org/10.1016/j.ygyno.2017.11.005 DO - 10.1016/j.ygyno.2017.11.005 ID - Shah2018 ER - TY - JOUR AU - Kuhlmann, J. D. AU - Chebouti, I. AU - Kimmig, R. AU - Buderath, P. AU - Reuter, M. AU - Puppel, S. -. H. PY - 2019 DA - 2019// TI - Extracellular vesicle-associated miRNAs in ovarian cancer—design of an integrated NGS-based workflow for the identification of blood-based biomarkers for platinum-resistance JO - Clin Chem Lab Med (CCLM) VL - 57 UR - https://doi.org/10.1515/cclm-2018-1048 DO - 10.1515/cclm-2018-1048 ID - Kuhlmann2019 ER - TY - JOUR AU - Zhang, Z. AU - Bast, R. C. AU - Yu, Y. AU - Li, J. AU - Sokoll, L. J. AU - Rai, A. J. PY - 2004 DA - 2004// TI - Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer JO - Cancer Res VL - 64 UR - https://doi.org/10.1158/0008-5472.CAN-04-0746 DO - 10.1158/0008-5472.CAN-04-0746 ID - Zhang2004 ER - TY - JOUR AU - Rai, A. J. AU - Zhang, Z. AU - Rosenzweig, J. AU - Shih, I. -. M. AU - Pham, T. AU - Fung, E. T. PY - 2002 DA - 2002// TI - Proteomic approaches to tumor marker discovery JO - Arch Pathol Lab Med VL - 126 ID - Rai2002 ER - TY - JOUR AU - Anderson, N. L. AU - Anderson, N. G. PY - 2002 DA - 2002// TI - The human plasma proteome JO - Mol Cell Proteom VL - 1 UR - https://doi.org/10.1074/mcp.R200007-MCP200 DO - 10.1074/mcp.R200007-MCP200 ID - Anderson2002 ER - TY - JOUR AU - Ignjatovic, V. AU - Geyer, P. E. AU - Palaniappan, K. K. AU - Chaaban, J. E. AU - Omenn, G. S. AU - Baker, M. S. PY - 2019 DA - 2019// TI - Mass spectrometry-based plasma proteomics: considerations from sample collection to achieving translational data JO - J Proteome Res VL - 18 UR - https://doi.org/10.1021/acs.jproteome.9b00503 DO - 10.1021/acs.jproteome.9b00503 ID - Ignjatovic2019 ER - TY - JOUR AU - Varki, A. PY - 2016 DA - 2016// TI - Biological roles of glycans JO - Glycobiology VL - 27 UR - https://doi.org/10.1093/glycob/cww086 DO - 10.1093/glycob/cww086 ID - Varki2016 ER - TY - JOUR AU - Tian, Y. AU - Zhou, Y. AU - Elliott, S. AU - Aebersold, R. AU - Zhang, H. PY - 2007 DA - 2007// TI - Solid-phase extraction of N-linked glycopeptides JO - Nat Protoc VL - 2 UR - https://doi.org/10.1038/nprot.2007.42 DO - 10.1038/nprot.2007.42 ID - Tian2007 ER - TY - JOUR AU - Kaji, H. AU - Saito, H. AU - Yamauchi, Y. AU - Shinkawa, T. AU - Taoka, M. AU - Hirabayashi, J. PY - 2003 DA - 2003// TI - Lectin affinity capture, isotope-coded tagging and mass spectrometry to identify N-linked glycoproteins JO - Nat Biotechnol VL - 21 UR - https://doi.org/10.1038/nbt829 DO - 10.1038/nbt829 ID - Kaji2003 ER - TY - JOUR AU - Sinha, A. AU - Hussain, A. AU - Ignatchenko, V. AU - Ignatchenko, A. AU - Tang, K. H. AU - Ho, V. W. H. PY - 2019 DA - 2019// TI - N-glycoproteomics of patient-derived xenografts: a strategy to discover tumor-associated proteins in high-grade serous ovarian cancer JO - Cell Syst VL - 8 UR - https://doi.org/10.1016/j.cels.2018.12.011 DO - 10.1016/j.cels.2018.12.011 ID - Sinha2019 ER - TY - JOUR AU - Dube, D. H. AU - Bertozzi, C. R. PY - 2005 DA - 2005// TI - Glycans in cancer and inflammation—potential for therapeutics and diagnostics JO - Nat Rev Drug Discov VL - 4 UR - https://doi.org/10.1038/nrd1751 DO - 10.1038/nrd1751 ID - Dube2005 ER - TY - JOUR AU - Biskup, K. AU - Braicu, E. I. AU - Sehouli, J. AU - Fotopoulou, C. AU - Tauber, R. AU - Berger, M. PY - 2013 DA - 2013// TI - Serum glycome profiling: a biomarker for diagnosis of ovarian cancer JO - J Proteome Res VL - 12 UR - https://doi.org/10.1021/pr400405x DO - 10.1021/pr400405x ID - Biskup2013 ER - TY - JOUR AU - Warburg, O. PY - 1956 DA - 1956// TI - On the origin of cancer cells JO - Science VL - 123 UR - https://doi.org/10.1126/science.123.3191.309 DO - 10.1126/science.123.3191.309 ID - Warburg1956 ER - TY - JOUR AU - Zhou, M. AU - Guan, W. AU - Walker, L. D. AU - Mezencev, R. AU - Benigno, B. B. AU - Gray, A. PY - 2010 DA - 2010// TI - Rapid mass spectrometric metabolic profiling of blood sera detects ovarian cancer with high accuracy JO - Cancer Epidemiol Biomark Prev VL - 19 UR - https://doi.org/10.1158/1055-9965.EPI-10-0126 DO - 10.1158/1055-9965.EPI-10-0126 ID - Zhou2010 ER - TY - JOUR AU - Buas, M. F. AU - Gu, H. AU - Djukovic, D. AU - Zhu, J. AU - Drescher, C. W. AU - Urban, N. PY - 2016 DA - 2016// TI - Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors JO - Gynecol Oncol VL - 140 UR - https://doi.org/10.1016/j.ygyno.2015.10.021 DO - 10.1016/j.ygyno.2015.10.021 ID - Buas2016 ER - TY - JOUR AU - Tetta, C. AU - Ghigo, E. AU - Silengo, L. AU - Deregibus, M. C. AU - Camussi, G. PY - 2012 DA - 2012// TI - Extracellular vesicles as an emerging mechanism of cell-to-cell communication JO - Endocrine VL - 44 UR - https://doi.org/10.1007/s12020-012-9839-0 DO - 10.1007/s12020-012-9839-0 ID - Tetta2012 ER - TY - JOUR AU - Taylor, D. D. AU - Gercel-Taylor, C. PY - 2008 DA - 2008// TI - MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer JO - Gynecol Oncol VL - 110 UR - https://doi.org/10.1016/j.ygyno.2008.04.033 DO - 10.1016/j.ygyno.2008.04.033 ID - Taylor2008 ER - TY - JOUR AU - Kobayashi, M. AU - Sawada, K. AU - Nakamura, K. AU - Yoshimura, A. AU - Miyamoto, M. AU - Shimizu, A. PY - 2018 DA - 2018// TI - Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types JO - J Ovarian Res VL - 11 UR - https://doi.org/10.1186/s13048-018-0458-0 DO - 10.1186/s13048-018-0458-0 ID - Kobayashi2018 ER - TY - JOUR AU - Peng, P. AU - Zhang, W. AU - Cao, D. AU - Yang, J. AU - Shen, K. PY - 2019 DA - 2019// TI - The proteomic comparison of peripheral circulation-derived exosomes from the epithelial ovarian carcinoma (EOC) patients and non-EOC subjects JO - Transl Cancer Res VL - 8 UR - https://doi.org/10.21037/tcr.2019.03.06 DO - 10.21037/tcr.2019.03.06 ID - Peng2019 ER - TY - JOUR AU - Poudineh, M. AU - Sargent, E. H. AU - Pantel, K. AU - Kelley, S. O. PY - 2018 DA - 2018// TI - Profiling circulating tumour cells and other biomarkers of invasive cancers JO - Nat Biomed Eng VL - 2 UR - https://doi.org/10.1038/s41551-018-0190-5 DO - 10.1038/s41551-018-0190-5 ID - Poudineh2018 ER - TY - JOUR AU - Liu, J. F. AU - Kindelberger, D. AU - Doyle, C. AU - Lowe, A. AU - Barry, W. T. AU - Matulonis, U. A. PY - 2013 DA - 2013// TI - Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients JO - Gynecol Oncol VL - 131 UR - https://doi.org/10.1016/j.ygyno.2013.08.006 DO - 10.1016/j.ygyno.2013.08.006 ID - Liu2013 ER - TY - JOUR AU - Pearl, M. L. AU - Zhao, Q. AU - Yang, J. AU - Dong, H. AU - Tulley, S. AU - Zhang, Q. PY - 2014 DA - 2014// TI - Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer JO - Gynecol Oncol VL - 134 UR - https://doi.org/10.1016/j.ygyno.2014.06.013 DO - 10.1016/j.ygyno.2014.06.013 ID - Pearl2014 ER - TY - JOUR AU - Lee, M. AU - Kim, E. J. AU - Cho, Y. AU - Kim, S. AU - Chung, H. H. AU - Park, N. H. PY - 2017 DA - 2017// TI - Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer JO - Gynecol Oncol VL - 145 UR - https://doi.org/10.1016/j.ygyno.2017.02.042 DO - 10.1016/j.ygyno.2017.02.042 ID - Lee2017 ER - TY - JOUR AU - Zhang, X. AU - Li, H. AU - Yu, X. AU - Li, S. AU - Lei, Z. AU - Li, C. PY - 2018 DA - 2018// TI - Analysis of circulating tumor cells in ovarian cancer and their clinical value as a biomarker JO - Cell Physiol Biochem VL - 48 UR - https://doi.org/10.1159/000492521 DO - 10.1159/000492521 ID - Zhang2018 ER - TY - JOUR AU - Miyamoto, D. T. AU - Zheng, Y. AU - Wittner, B. S. AU - Lee, R. J. AU - Zhu, H. AU - Broderick, K. T. PY - 2015 DA - 2015// TI - RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance JO - Science VL - 349 UR - https://doi.org/10.1126/science.aab0917 DO - 10.1126/science.aab0917 ID - Miyamoto2015 ER - TY - JOUR AU - Cheng, Y. -. H. AU - Chen, Y. -. C. AU - Lin, E. AU - Brien, R. AU - Jung, S. AU - Chen, Y. -. T. PY - 2019 DA - 2019// TI - Hydro-Seq enables contamination-free high-throughput single-cell RNA-sequencing for circulating tumor cells JO - Nat Commun VL - 10 UR - https://doi.org/10.1038/s41467-018-07882-8 DO - 10.1038/s41467-018-07882-8 ID - Cheng2019 ER - TY - JOUR AU - Li, S. AU - Plouffe, B. D. AU - Belov, A. M. AU - Ray, S. AU - Wang, X. AU - Murthy, S. K. PY - 2015 DA - 2015// TI - An integrated platform for isolation, processing, and mass spectrometry-based proteomic profiling of rare cells in whole blood JO - Mol Cell Proteom VL - 14 UR - https://doi.org/10.1074/mcp.M114.045724 DO - 10.1074/mcp.M114.045724 ID - Li2015 ER - TY - JOUR AU - Zhu, Y. AU - Podolak, J. AU - Zhao, R. AU - Shukla, A. K. AU - Moore, R. J. AU - Thomas, G. V. PY - 2018 DA - 2018// TI - Proteome profiling of 1 to 5 spiked circulating tumor cells isolated from whole blood using immunodensity enrichment, laser capture microdissection, nanodroplet sample processing, and ultrasensitive nanoLC-MS JO - Anal Chem VL - 90 UR - https://doi.org/10.1021/acs.analchem.8b03268 DO - 10.1021/acs.analchem.8b03268 ID - Zhu2018 ER - TY - JOUR AU - Ghisoni, E. AU - Imbimbo, M. AU - Zimmermann, S. AU - Valabrega, G. PY - 2019 DA - 2019// TI - Ovarian cancer immunotherapy: turning up the heat JO - IJMS VL - 20 UR - https://doi.org/10.3390/ijms20122927 DO - 10.3390/ijms20122927 ID - Ghisoni2019 ER - TY - JOUR AU - Lutz, R. J. PY - 2015 DA - 2015// TI - Targeting the folate receptor for the treatment of ovarian cancer JO - Transl Cancer Res VL - 4 ID - Lutz2015 ER - TY - JOUR AU - Dvorak, H. F. AU - Brown, L. F. AU - Detmar, M. AU - Dvorak, A. M. PY - 1995 DA - 1995// TI - Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis JO - Am J Pathol VL - 146 ID - Dvorak1995 ER - TY - JOUR AU - Ferrara, N. AU - Hillan, K. J. AU - Gerber, H. -. P. AU - Novotny, W. PY - 2004 DA - 2004// TI - Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer JO - Nat Rev Drug Discov VL - 3 UR - https://doi.org/10.1038/nrd1381 DO - 10.1038/nrd1381 ID - Ferrara2004 ER - TY - JOUR AU - Hurwitz, H. AU - Fehrenbacher, L. AU - Novotny, W. AU - Cartwright, T. AU - Hainsworth, J. AU - Heim, W. PY - 2004 DA - 2004// TI - Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer JO - N Engl J Med VL - 350 UR - https://doi.org/10.1056/NEJMoa032691 DO - 10.1056/NEJMoa032691 ID - Hurwitz2004 ER - TY - JOUR AU - Atkins, M. B. PY - 2005 DA - 2005// TI - Management of advanced renal cancer JO - Kidney Int VL - 67 UR - https://doi.org/10.1111/j.1523-1755.2005.00309.x DO - 10.1111/j.1523-1755.2005.00309.x ID - Atkins2005 ER - TY - JOUR AU - Burger, R. A. AU - Brady, M. F. AU - Bookman, M. A. AU - Fleming, G. F. AU - Monk, B. J. AU - Huang, H. PY - 2011 DA - 2011// TI - Incorporation of bevacizumab in the primary treatment of ovarian cancer JO - N Engl J Med VL - 365 UR - https://doi.org/10.1056/NEJMoa1104390 DO - 10.1056/NEJMoa1104390 ID - Burger2011 ER - TY - JOUR AU - Perren, T. J. AU - Swart, A. M. AU - Pfisterer, J. AU - Ledermann, J. A. AU - Pujade-Lauraine, E. AU - Kristensen, G. PY - 2011 DA - 2011// TI - A phase 3 trial of bevacizumab in ovarian cancer JO - N Engl J Med VL - 365 UR - https://doi.org/10.1056/NEJMoa1103799 DO - 10.1056/NEJMoa1103799 ID - Perren2011 ER - TY - JOUR AU - Oza, A. M. AU - Cook, A. D. AU - Pfisterer, J. AU - Embleton, A. AU - Ledermann, J. A. AU - Pujade-Lauraine, E. PY - 2015 DA - 2015// TI - Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)00086-8 DO - 10.1016/S1470-2045(15)00086-8 ID - Oza2015 ER - TY - JOUR AU - Tewari, K. S. AU - Burger, R. A. AU - Enserro, D. AU - Norquist, B. M. AU - Swisher, E. M. AU - Brady, M. F. PY - 2019 DA - 2019// TI - Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.19.01009 DO - 10.1200/JCO.19.01009 ID - Tewari2019 ER - TY - JOUR AU - Aghajanian, C. AU - Blank, S. V. AU - Goff, B. A. AU - Judson, P. L. AU - Teneriello, M. G. AU - Husain, A. PY - 2012 DA - 2012// TI - OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2012.42.0505 DO - 10.1200/JCO.2012.42.0505 ID - Aghajanian2012 ER - TY - JOUR AU - Pujade-Lauraine, E. AU - Hilpert, F. AU - Weber, B. AU - Reuss, A. AU - Poveda, A. AU - Kristensen, G. PY - 2014 DA - 2014// TI - Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.51.4489 DO - 10.1200/JCO.2013.51.4489 ID - Pujade-Lauraine2014 ER - TY - JOUR AU - Aghajanian, C. AU - Goff, B. AU - Nycum, L. R. AU - Wang, Y. V. AU - Husain, A. AU - Blank, S. V. PY - 2015 DA - 2015// TI - Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer JO - Gynecol Oncol VL - 139 UR - https://doi.org/10.1016/j.ygyno.2015.08.004 DO - 10.1016/j.ygyno.2015.08.004 ID - Aghajanian2015 ER - TY - JOUR AU - Bois, A. AU - Floquet, A. AU - Kim, J. -. W. AU - Rau, J. AU - Campo, J. M. AU - Friedlander, M. PY - 2014 DA - 2014// TI - Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2014.55.7348 DO - 10.1200/JCO.2014.55.7348 ID - Bois2014 ER - TY - JOUR AU - Ray Coquard, I. AU - Cibula, D. AU - Mirza, M. R. AU - Reuss, A. AU - Ricci, C. AU - Colombo, N. PY - 2019 DA - 2019// TI - Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer JO - Int J Cancer VL - 146 UR - https://doi.org/10.1002/ijc.32606 DO - 10.1002/ijc.32606 ID - Ray Coquard2019 ER - TY - JOUR AU - Chambon, P. AU - Weill, J. D. AU - Doly, J. AU - Strosser, M. T. AU - Mandel, P. PY - 1966 DA - 1966// TI - On the formation of a novel adenylic compound by enzymatic extracts of liver nuclei JO - Biochem Biophys Res Commun VL - 25 UR - https://doi.org/10.1016/0006-291X(66)90502-X DO - 10.1016/0006-291X(66)90502-X ID - Chambon1966 ER - TY - JOUR AU - Kraus, W. L. PY - 2015 DA - 2015// TI - PARPs and ADP-ribosylation: 50 years … and counting JO - Mol Cell VL - 58 UR - https://doi.org/10.1016/j.molcel.2015.06.006 DO - 10.1016/j.molcel.2015.06.006 ID - Kraus2015 ER - TY - JOUR AU - Helleday, T. AU - Petermann, E. AU - Lundin, C. AU - Hodgson, B. AU - Sharma, R. A. PY - 2008 DA - 2008// TI - DNA repair pathways as targets for cancer therapy JO - Nat Rev Cancer VL - 8 UR - https://doi.org/10.1038/nrc2342 DO - 10.1038/nrc2342 ID - Helleday2008 ER - TY - JOUR AU - Farmer, H. AU - McCabe, N. AU - Lord, C. J. AU - Tutt, A. N. J. AU - Johnson, D. A. AU - Richardson, T. B. PY - 2005 DA - 2005// TI - Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy JO - Nature VL - 434 UR - https://doi.org/10.1038/nature03445 DO - 10.1038/nature03445 ID - Farmer2005 ER - TY - JOUR AU - Ledermann, J. AU - Harter, P. AU - Gourley, C. AU - Friedlander, M. AU - Vergote, I. AU - Rustin, G. PY - 2012 DA - 2012// TI - Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1105535 DO - 10.1056/NEJMoa1105535 ID - Ledermann2012 ER - TY - JOUR AU - Pujade-Lauraine, E. AU - Ledermann, J. A. AU - Selle, F. AU - Gebski, V. AU - Penson, R. T. AU - Oza, A. M. PY - 2017 DA - 2017// TI - Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/S1470-2045(17)30469-2 DO - 10.1016/S1470-2045(17)30469-2 ID - Pujade-Lauraine2017 ER - TY - JOUR AU - Mirza, M. R. AU - Monk, B. J. AU - Herrstedt, J. AU - Oza, A. M. AU - Mahner, S. AU - Redondo, A. PY - 2016 DA - 2016// TI - Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1611310 DO - 10.1056/NEJMoa1611310 ID - Mirza2016 ER - TY - JOUR AU - González Martin, A. AU - Pothuri, B. AU - Vergote, I. AU - DePont, C. R. AU - Graybill, W. AU - Mirza, M. R. PY - 2019 DA - 2019// TI - Niraparib in patients with newly diagnosed advanced ovarian cancer JO - N Engl J Med VL - 381 UR - https://doi.org/10.1056/NEJMoa1910962 DO - 10.1056/NEJMoa1910962 ID - González Martin2019 ER - TY - JOUR AU - Coscia, F. AU - Lengyel, E. AU - Duraiswamy, J. AU - Ashcroft, B. AU - Bassani-Sternberg, M. AU - Wierer, M. PY - 2018 DA - 2018// TI - Multi-level proteomics identifies CT45 as a chemosensitivity mediator and immunotherapy target in ovarian cancer JO - Cell VL - 175 UR - https://doi.org/10.1016/j.cell.2018.08.065 DO - 10.1016/j.cell.2018.08.065 ID - Coscia2018 ER - TY - JOUR AU - Scannell, J. W. AU - Blanckley, A. AU - Boldon, H. AU - Warrington, B. PY - 2012 DA - 2012// TI - Diagnosing the decline in pharmaceutical R&D efficiency JO - Nat Rev Drug Discov VL - 11 UR - https://doi.org/10.1038/nrd3681 DO - 10.1038/nrd3681 ID - Scannell2012 ER - TY - JOUR AU - Kurimchak, A. M. AU - Herrera-Montávez, C. AU - Brown, J. AU - Johnson, K. J. AU - Sodi, V. AU - Srivastava, N. PY - 2020 DA - 2020// TI - Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma JO - Sci Signal VL - 13 UR - https://doi.org/10.1126/scisignal.aax8238 DO - 10.1126/scisignal.aax8238 ID - Kurimchak2020 ER - TY - STD TI - The Human Protein Atlas. The druggable proteome. https://proteinatlas.org/humanproteome/tissue/druggable UR - http://proteinatlas.org/humanproteome/tissue/druggable ID - ref165 ER - TY - JOUR AU - Diamantis, N. AU - Banerji, U. PY - 2016 DA - 2016// TI - Antibody–drug conjugates—an emerging class of cancer treatment JO - Br J Cancer VL - 114 UR - https://doi.org/10.1038/bjc.2015.435 DO - 10.1038/bjc.2015.435 ID - Diamantis2016 ER - TY - JOUR AU - Peters, C. AU - Brown, S. PY - 2015 DA - 2015// TI - Antibody–drug conjugates as novel anti-cancer chemotherapeutics JO - Biosci Rep VL - 35 UR - https://doi.org/10.1042/BSR20150089 DO - 10.1042/BSR20150089 ID - Peters2015 ER - TY - JOUR AU - Moore, K. N. AU - Vergote, I. AU - Oaknin, A. AU - Colombo, N. AU - Banerjee, S. AU - Oza, A. PY - 2018 DA - 2018// TI - FORWARD I: a phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer JO - Future Oncol VL - 14 UR - https://doi.org/10.2217/fon-2017-0646 DO - 10.2217/fon-2017-0646 ID - Moore2018 ER - TY - JOUR AU - Sato, S. AU - Itamochi, H. PY - 2016 DA - 2016// TI - Profile of farletuzumab and its potential in the treatment of solid tumors JO - Onco Targets Ther VL - 9 UR - https://doi.org/10.2147/OTT.S98242 DO - 10.2147/OTT.S98242 ID - Sato2016 ER - TY - JOUR AU - Marcotte, R. AU - Brown, K. R. AU - Suarez, F. AU - Sayad, A. AU - Karamboulas, K. AU - Krzyzanowski, P. M. PY - 2012 DA - 2012// TI - Essential gene profiles in breast, pancreatic, and ovarian cancer cells JO - Cancer Discov VL - 2 UR - https://doi.org/10.1158/2159-8290.CD-11-0224 DO - 10.1158/2159-8290.CD-11-0224 ID - Marcotte2012 ER - TY - JOUR AU - Behan, F. M. AU - Iorio, F. AU - Picco, G. AU - Alves, E. G. X. AU - Beaver, C. M. AU - Migliardi, G. PY - 2019 DA - 2019// TI - Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens JO - Nature VL - 568 UR - https://doi.org/10.1038/s41586-019-1103-9 DO - 10.1038/s41586-019-1103-9 ID - Behan2019 ER - TY - JOUR AU - Cheung, H. W. AU - Cowley, G. S. AU - Weir, B. A. AU - Boehm, J. S. AU - Rusin, S. AU - Scott, J. A. PY - 2011 DA - 2011// TI - Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer JO - Proc Natl Acad Sci USA VL - 108 UR - https://doi.org/10.1073/pnas.1109363108 DO - 10.1073/pnas.1109363108 ID - Cheung2011 ER - TY - JOUR AU - Fang, P. AU - Souza, C. AU - Minn, K. AU - Chien, J. PY - 2019 DA - 2019// TI - Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity JO - Commun Biol VL - 2 UR - https://doi.org/10.1038/s42003-018-0242-0 DO - 10.1038/s42003-018-0242-0 ID - Fang2019 ER - TY - JOUR AU - Mengwasser, K. E. AU - Adeyemi, R. O. AU - Leng, Y. AU - Choi, M. Y. AU - Clairmont, C. AU - D'Andrea, A. D. PY - 2019 DA - 2019// TI - Genetic screens reveal FEN1 and APEX2 as BRCA2 synthetic lethal targets JO - Mol Cell VL - 73 UR - https://doi.org/10.1016/j.molcel.2018.12.008 DO - 10.1016/j.molcel.2018.12.008 ID - Mengwasser2019 ER - TY - JOUR AU - Baratta, M. G. AU - Schinzel, A. C. AU - Zwang, Y. AU - Bandopadhayay, P. AU - Bowman-Colin, C. AU - Kutt, J. PY - 2015 DA - 2015// TI - An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma JO - Proc Natl Acad Sci USA VL - 112 UR - https://doi.org/10.1073/pnas.1422165112 DO - 10.1073/pnas.1422165112 ID - Baratta2015 ER - TY - JOUR AU - Kenny, H. A. AU - Lal-Nag, M. AU - Shen, M. AU - Kara, B. AU - Nahotko, D. A. AU - Wroblewski, K. PY - 2020 DA - 2020// TI - Quantitative high-throughput screening using an organotypic model identifies compounds that inhibit ovarian cancer metastasis JO - Mol Cancer Ther VL - 19 UR - https://doi.org/10.1158/1535-7163.MCT-19-0052 DO - 10.1158/1535-7163.MCT-19-0052 ID - Kenny2020 ER - TY - JOUR AU - Zeng, M. AU - Kwiatkowski, N. P. AU - Zhang, T. AU - Nabet, B. AU - Xu, M. AU - Liang, Y. PY - 2018 DA - 2018// TI - Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. Sawyers CL, Levine RL, editors JO - Elife VL - 7 UR - https://doi.org/10.7554/eLife.39030 DO - 10.7554/eLife.39030 ID - Zeng2018 ER - TY - JOUR AU - Waas, M. AU - Snarrenberg, S. T. AU - Littrell, J. AU - Jones Lipinski, R. A. AU - Hansen, P. A. AU - Corbett, J. A. PY - 2020 DA - 2020// TI - SurfaceGenie: a web-based application for prioritizing cell-type-specific marker candidates JO - Bioinformatics VL - 36 UR - https://doi.org/10.1093/bioinformatics/btaa092 DO - 10.1093/bioinformatics/btaa092 ID - Waas2020 ER - TY - JOUR AU - Medrano, M. AU - Communal, L. AU - Brown, K. R. AU - Iwanicki, M. AU - Normand, J. AU - Paterson, J. PY - 2017 DA - 2017// TI - Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer JO - Cell Rep VL - 18 UR - https://doi.org/10.1016/j.celrep.2017.02.028 DO - 10.1016/j.celrep.2017.02.028 ID - Medrano2017 ER - TY - JOUR AU - Martinko, A. J. AU - Truillet, C. AU - Julien, O. AU - Diaz, J. E. AU - Horlbeck, M. A. AU - Whiteley, G. PY - 2018 DA - 2018// TI - Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins JO - Elife VL - 7 UR - https://doi.org/10.7554/eLife.31098 DO - 10.7554/eLife.31098 ID - Martinko2018 ER - TY - JOUR AU - Lengyel, E. AU - Burdette, J. E. AU - Kenny, H. A. AU - Matei, D. AU - Pilrose, J. AU - Haluska, P. PY - 2014 DA - 2014// TI - Epithelial ovarian cancer experimental models JO - Oncogene VL - 33 UR - https://doi.org/10.1038/onc.2013.321 DO - 10.1038/onc.2013.321 ID - Lengyel2014 ER - TY - JOUR AU - Domcke, S. AU - Sinha, R. AU - Levine, D. A. AU - Sander, C. AU - Schultz, N. PY - 2013 DA - 2013// TI - Evaluating cell lines as tumour models by comparison of genomic profiles JO - Nat Commun VL - 4 UR - https://doi.org/10.1038/ncomms3126 DO - 10.1038/ncomms3126 ID - Domcke2013 ER - TY - JOUR AU - Coscia, F. AU - Watters, K. M. AU - Curtis, M. AU - Eckert, M. A. AU - Chiang, C. Y. AU - Tyanova, S. PY - 2016 DA - 2016// TI - Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status JO - Nat Commun VL - 7 UR - https://doi.org/10.1038/ncomms12645 DO - 10.1038/ncomms12645 ID - Coscia2016 ER - TY - JOUR AU - Mitra, A. K. AU - Davis, D. A. AU - Tomar, S. AU - Roy, L. AU - Gurler, H. AU - Xie, J. PY - 2015 DA - 2015// TI - In vivo tumor growth of high-grade serous ovarian cancer cell lines JO - Gynecol Oncol VL - 138 UR - https://doi.org/10.1016/j.ygyno.2015.05.040 DO - 10.1016/j.ygyno.2015.05.040 ID - Mitra2015 ER - TY - JOUR AU - Elias, K. M. AU - Emori, M. M. AU - Papp, E. AU - MacDuffie, E. AU - Konecny, G. E. AU - Velculescu, V. E. PY - 2015 DA - 2015// TI - Beyond genomics: critical evaluation of cell line utility for ovarian cancer research JO - Gynecol Oncol VL - 139 UR - https://doi.org/10.1016/j.ygyno.2015.08.017 DO - 10.1016/j.ygyno.2015.08.017 ID - Elias2015 ER - TY - JOUR AU - Pampaloni, F. AU - Reynaud, E. G. AU - Stelzer, E. H. K. PY - 2007 DA - 2007// TI - The third dimension bridges the gap between cell culture and live tissue JO - Nat Rev Mol Cell Biol VL - 8 UR - https://doi.org/10.1038/nrm2236 DO - 10.1038/nrm2236 ID - Pampaloni2007 ER - TY - JOUR AU - Tevis, K. M. AU - Colson, Y. L. AU - Grinstaff, M. W. PY - 2017 DA - 2017// TI - Embedded spheroids as models of the cancer microenvironment JO - Adv Biosyst VL - 1 UR - https://doi.org/10.1002/adbi.201700083 DO - 10.1002/adbi.201700083 ID - Tevis2017 ER - TY - JOUR AU - Hussain, A. AU - Voisin, V. AU - Poon, S. AU - Karamboulas, C. AU - Bui, N. H. B. AU - Meens, J. PY - 2020 DA - 2020// TI - Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21 JO - J Exp Med. VL - 217 UR - https://doi.org/10.1084/jem.20191094 DO - 10.1084/jem.20191094 ID - Hussain2020 ER - TY - JOUR AU - Hart, P. C. AU - Kenny, H. A. AU - Grassl, N. AU - Watters, K. M. AU - Litchfield, L. M. AU - Coscia, F. PY - 2019 DA - 2019// TI - Mesothelial cell HIF1a expression is metabolically downregulated by metformin to prevent oncogenic tumor-stromal crosstalk JO - Cell Rep VL - 29 UR - https://doi.org/10.1016/j.celrep.2019.11.079 DO - 10.1016/j.celrep.2019.11.079 ID - Hart2019 ER - TY - JOUR AU - Kenny, H. A. AU - Dogan, S. AU - Zillhardt, M. AU - Mitra, A. AU - Yamada, S. D. AU - Krausz, T. PY - 2009 DA - 2009// TI - Organotypic models of metastasis: a three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis JO - Cancer Treat Res VL - 149 UR - https://doi.org/10.1007/978-0-387-98094-2_16 DO - 10.1007/978-0-387-98094-2_16 ID - Kenny2009 ER - TY - JOUR AU - Liao, J. AU - Qian, F. AU - Tchabo, N. AU - Mhawech-Fauceglia, P. AU - Beck, A. AU - Qian, Z. PY - 2014 DA - 2014// TI - Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism. Orsulic S, editor JO - PLoS ONE VL - 9 UR - https://doi.org/10.1371/journal.pone.0084941 DO - 10.1371/journal.pone.0084941 ID - Liao2014 ER - TY - JOUR AU - Kopper, O. AU - Witte, C. J. AU - Lõhmussaar, K. AU - Valle-Inclan, J. E. AU - Hami, N. AU - Kester, L. PY - 2019 DA - 2019// TI - An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity JO - Nat Med VL - 25 UR - https://doi.org/10.1038/s41591-019-0422-6 DO - 10.1038/s41591-019-0422-6 ID - Kopper2019 ER - TY - JOUR AU - Jones, P. M. AU - Drapkin, R. PY - 2013 DA - 2013// TI - Modeling high-grade serous carcinoma: how converging insights into pathogenesis and genetics are driving better experimental platforms JO - Front Oncol VL - 3 UR - https://doi.org/10.3389/fonc.2013.00217 DO - 10.3389/fonc.2013.00217 ID - Jones2013 ER - TY - JOUR AU - Kim, J. AU - Coffey, D. M. AU - Creighton, C. J. AU - Yu, Z. AU - Hawkins, S. M. AU - Matzuk, M. M. PY - 2012 DA - 2012// TI - High-grade serous ovarian cancer arises from fallopian tube in a mouse model JO - Proc Natl Acad Sci USA VL - 109 UR - https://doi.org/10.1073/pnas.1117135109 DO - 10.1073/pnas.1117135109 ID - Kim2012 ER - TY - JOUR AU - Zhai, Y. AU - Wu, R. AU - Kuick, R. AU - Sessine, M. S. AU - Schulman, S. AU - Green, M. PY - 2017 DA - 2017// TI - High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease JO - J Pathol VL - 243 UR - https://doi.org/10.1002/path.4927 DO - 10.1002/path.4927 ID - Zhai2017 ER - TY - JOUR AU - Perets, R. AU - Wyant, G. A. AU - Muto, K. W. AU - Bijron, J. G. AU - Poole, B. B. AU - Chin, K. T. PY - 2013 DA - 2013// TI - Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models JO - Cancer Cell VL - 24 UR - https://doi.org/10.1016/j.ccr.2013.10.013 DO - 10.1016/j.ccr.2013.10.013 ID - Perets2013 ER - TY - JOUR AU - Sherman-Baust, C. A. AU - Kuhn, E. AU - Valle, B. L. AU - Shih, I. -. M. AU - Kurman, R. J. AU - Wang, T. -. L. PY - 2014 DA - 2014// TI - A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development JO - J Pathol VL - 233 UR - https://doi.org/10.1002/path.4353 DO - 10.1002/path.4353 ID - Sherman-Baust2014 ER - TY - JOUR AU - Kopetz, S. AU - Lemos, R. AU - Powis, G. PY - 2012 DA - 2012// TI - The promise of patient-derived xenografts: the best laid plans of mice and men JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-12-2408 DO - 10.1158/1078-0432.CCR-12-2408 ID - Kopetz2012 ER - TY - JOUR AU - Hoffman, R. M. PY - 2015 DA - 2015// TI - Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts JO - Nat Rev Cancer VL - 15 UR - https://doi.org/10.1038/nrc3972 DO - 10.1038/nrc3972 ID - Hoffman2015 ER - TY - JOUR AU - Shaw, T. J. AU - Senterman, M. K. AU - Dawson, K. AU - Crane, C. A. AU - Vanderhyden, B. C. PY - 2004 DA - 2004// TI - Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer JO - Mol Ther VL - 10 UR - https://doi.org/10.1016/j.ymthe.2004.08.013 DO - 10.1016/j.ymthe.2004.08.013 ID - Shaw2004 ER - TY - JOUR AU - Ricci, F. AU - Bizzaro, F. AU - Cesca, M. AU - Guffanti, F. AU - Ganzinelli, M. AU - Decio, A. PY - 2014 DA - 2014// TI - Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations JO - Cancer Res VL - 74 UR - https://doi.org/10.1158/0008-5472.CAN-14-0274 DO - 10.1158/0008-5472.CAN-14-0274 ID - Ricci2014 ER - TY - JOUR AU - Topp, M. D. AU - Hartley, L. AU - Cook, M. AU - Heong, V. AU - Boehm, E. AU - McShane, L. PY - 2014 DA - 2014// TI - Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts JO - Mol Oncol VL - 8 UR - https://doi.org/10.1016/j.molonc.2014.01.008 DO - 10.1016/j.molonc.2014.01.008 ID - Topp2014 ER - TY - JOUR AU - Weroha, S. J. AU - Becker, M. A. AU - Enderica-Gonzalez, S. AU - Harrington, S. C. AU - Oberg, A. L. AU - Maurer, M. J. PY - 2014 DA - 2014// TI - Tumorgrafts as in vivo surrogates for women with ovarian cancer JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-2611 DO - 10.1158/1078-0432.CCR-13-2611 ID - Weroha2014 ER - TY - JOUR AU - Moldovan, L. AU - Batte, K. E. AU - Trgovcich, J. AU - Wisler, J. AU - Marsh, C. B. AU - Piper, M. PY - 2014 DA - 2014// TI - Methodological challenges in utilizing miRNAs as circulating biomarkers JO - J Cell Mol Med VL - 18 UR - https://doi.org/10.1111/jcmm.12236 DO - 10.1111/jcmm.12236 ID - Moldovan2014 ER - TY - JOUR AU - Wright, A. A. AU - Bohlke, K. AU - Armstrong, D. K. AU - Bookman, M. A. AU - Cliby, W. A. AU - Coleman, R. L. PY - 2016 DA - 2016// TI - Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.68.6907 DO - 10.1200/JCO.2016.68.6907 ID - Wright2016 ER -